PHOTO
Abu Dhabi: The Emirati company "G20" signed a strategic partnership agreement with the American company PharmXGen, so that "G20" will be the exclusive agent to supply and distribute in the Middle East and North Africa the newest Rapid Antigen tests in the world.
The agreement was signed by His Excellency Dr. Mubarak Hamad Marzouq Al Ameri, Chairman of the Board of Directors of the Emirati G20 company, and Mr. Bill Henwood, President of the American company PharmXGen, at the headquarters of the G20 Company in Abu Dhabi.
On this occasion, his Excellency Dr. Mubarak Hamad Marzouq Al Ameri said: “We are very pleased to cooperate with the American company PharmXGen, and we will be the exclusive agent for the company’s innovative intranasal Rapid Antigen tests, as they achieve speed in showing the test results in a period of time ranging from 3-10 minutes as a maximum, with a 100% efficiency. These tests have been approved by the US Food and Drug Administration, and they are used in the United States of America, the United Kingdom, Germany and a number of countries in the world.
Dr. Al-Ameri added: “The new screening tests are very important since they are the fastest in showing the results, whether negative or positive. In fact, the results appear in a maximum of 10 minutes, which allows a rapid gradual return to normal life. Indeed, the new tests will help organizing events and activities and speeding up entry to government and private institutions and facilities, whether airports, hospitals, or the headquarters of institutions and departments.”
Dr. Al Ameri explained that the speed of obtaining quick results will give the individuals more confidence and security and help them to follow the precautionary measures established by the concerned authorities, which promotes a sense of confidence, and allows work and movement in a safe environment.
Mr. Bill Henwood said: “We are pleased to cooperate with the Emirati company G20, which will be the exclusive agent for our products, especially those related to Rapid Antigen tests, as we have succeeded in creating and developing innovations that can show the results within 10 minutes, which is considered the fastest in the world, with a 100% efficiency”.
He added, "The tests manufactured by the company are approved by the US Food and Drug Administration and used in a number of countries, most notably the United States of America, the United Kingdom, Germany, China and other countries, and we are very happy that our tests will be used in the Middle East and North Africa, which will save time, and herald a rapid gradual return to normal life. These tests can be used by travelers, visitors to events and activities and exhibitions, and ordinary individuals who need quick and accurate results.”
-Ends-
PRESS INQUIRIES
Mr. Ammar Adra (mobile: +971 52 9564041)
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
